Down-regulation of GADD45A enhances chemosensitivity in melanoma

Sci Rep. 2018 Mar 7;8(1):4111. doi: 10.1038/s41598-018-22484-6.

Abstract

Melanoma is a malignant skin cancer with considerable drug resistance. Increased expression of DNA repair genes have been reported in melanoma, and this contributes to chemotherapy resistance. GADD45A is involved in DNA repair, cell cycle arrest and apoptosis in response to physiologic or environmental stresses. In this study, we investigated the role of GADD45A in chemotherapy response. Firstly, the mRNA expression of profiled DNA repair genes in cisplatin-treated melanoma cells was detected by RT2 profilerTM PCR array. We found the expression of GADD45A upregulated in a dose- and time- dependent manner. In addition, suppression of GADD45A sensitized melanoma cells to cisplatin and enhanced cisplatin-induced DNA damage. Flow cytometry revealed that downregulating GADD45A released cells from cisplatin-induced G2/M arrest and increased apoptosis. By using a MEK inhibitor, GADD45A was shown to be regulated by MAPK-ERK pathway following cisplatin treatment. Thus, the induction of GADD45A might play important roles in chemotherapy response in human melanoma cancer and could serve as a novel molecular target for melanoma therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Cell Cycle Proteins / biosynthesis*
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • Down-Regulation / drug effects*
  • Drug Resistance, Neoplasm / drug effects*
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Humans
  • M Phase Cell Cycle Checkpoints / drug effects
  • Melanoma* / drug therapy
  • Melanoma* / metabolism
  • Melanoma* / pathology
  • Neoplasm Proteins / biosynthesis*
  • Nuclear Proteins / biosynthesis*

Substances

  • Cell Cycle Proteins
  • GADD45A protein, human
  • Neoplasm Proteins
  • Nuclear Proteins
  • Cisplatin